Table 3 Follow-up data for patients treated with corticosteroid therapy
Corticosteroid group (n = 40) | ||
|---|---|---|
ESKD (yes) | 40 (100) | |
RAS blockade (yes) | 38 (95) | |
UACR (mg/mmol) before RAS blockade | 508 (248–717) | |
UACR (mg/mmol) after RAS blockade | 210 (133–536) | |
eGFR (mL/min/1.73 m2) before corticosteroid treatment | 21 (13–46) | |
eGFR (mL/min/1.73 m2) immediately after corticosteroid treatment | 20 (12–40) | |
≥ 50% decrease in eGFR during treatment | 5 (13) | |
≥ 50% decrease in eGFR from diagnosis until immediately after corticosteroid treatment | 17 (43) | |
eGFR (mL/min/1.73 m2) immediately after corticosteroid treatment | > 90 | 2 (5.0) |
60–89 | 1 (3) | |
45–59 | 5 (13) | |
30–44 | 8 (20) | |
< 30 | 24 (60) | |
Proteinuria (g/24 h) before corticosteroid treatment | 5.5 (3.4–7.3) | |
Proteinuria (g/24 h) immediately after corticosteroid treatment | 3.0 (1.8–5.2) | |
Reduction in proteinuria (g/24 h) during corticosteroid treatment | 1.9 (0.9–3.4) | |
Adverse effects | None | 5 (13) |
Mild | 26 (65) | |
Severe | 9 (23) | |